Overactive Detrusor Clinical Trial
Official title:
Prognostic Value of the Urinary Nerve Growth Factor (NGF) in the Patients With Benign Prostatic Hyperplasia (BPH) Who Undergo Holmium Laser Enucleation of the Prostate (HoLEP)
Persistent detrusor overactivity (DO) after transurethral prostatectomy results in
symptomatic failure in more than one third of the patients. Storage symptoms are major
complaints in the early postoperative period after Holmium Laser Enucleation of the Prostate
(HoLEP). Levels of the urinary nerve growth factor (NGF), produced by bladder urothelium and
smooth muscle, are increased in the patients with overactive bladder (OAB), and decreased
after the OAB symptoms were improved. Also, urinary NGF levels are increased in patients with
benign prostatic obstruction (BPO), but the changes of the NGF levels after relief of the BPO
by the medical or surgical treatment have not been fully investigated. If the elevated
urinary NGF levels are reduced after successful surgical treatment of BPO, measurement of
urinary NGF could be a useful objective tool to assess the therapeutic outcomes of the
operation.
The aims of this study are to measure the urinary NGF levels in patients with BPO and to
compare the results between the patients with detrusor overactivity (DO) and without detrusor
overactivity (Non-DO), average 2 weeks before Holmium Laser Enucleation of the Prostate
(HoLEP) procedure. After HoLEP, urinary NGF levels are rechecked at the periods of
postoperative 3 months and 6 months, and compare changes between the two groups.
- Investigators are going to enroll age-matched control group and measure the urinary NGF
levels as a baseline value (30 males).
- Investigators are going to enroll BPO patients group (DO group 50 and Non-DO group 50
patients).
- Administration of the anti-cholinergic agents was reported to decrease urinary NGF
levels. Investigators are going to try to avoid the effect of anti-muscarinic drugs.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT05977634 -
Transcutaneous Tibial Nerve Stimulation for Idiopathic Overactive Bladder
|
N/A | |
| Completed |
NCT02657057 -
Effects of Transcutaneous and Percutaneous PTNS on Idiopathic OAB
|
N/A | |
| Completed |
NCT01192568 -
Safety and Efficacy Evaluation of Oxybutynin Topical Gel In Children With Neurogenic Bladder
|
Phase 4 | |
| Completed |
NCT01837654 -
Plantarflexion Reduces Urgency and Peak Detrusor Pressure in Patients With Detrusor Overactivity
|
N/A | |
| Recruiting |
NCT05895045 -
Yoga for Treatment of Overactive Bladder in Pediatric Patients
|
N/A | |
| Completed |
NCT03451175 -
Reproductibility of Cystometry in Multiple Sclerosis Patient
|
N/A | |
| Terminated |
NCT03080389 -
Sensitivity of Extended Cultures in Diagnosing Urinary Tract Infections
|
||
| Completed |
NCT01629433 -
Onabotulinumtoxina Intradetrusorial Injections and NGF Expression
|
Phase 4 | |
| Terminated |
NCT00845338 -
Study of Darifenacin in Patients Suffering From Multiple Sclerosis and Neurogenic Detrusor Overactivity
|
Phase 2 | |
| Completed |
NCT03388086 -
Efficacy of Two Onabotulinum Toxin Doses
|
||
| Completed |
NCT04197466 -
Comparison of Different Treatments for Overactive Bladder Syndrome
|
N/A | |
| Not yet recruiting |
NCT02009540 -
Botulinum Toxin in the Treatment of Idiopathic Detrusor Overactivity
|
Phase 4 | |
| Completed |
NCT04270526 -
Minimizing Pain During Office Intradetrussor Botox Injection
|
Phase 4 | |
| Enrolling by invitation |
NCT06212661 -
Migraine Medication Effects on Urinary Symptoms
|
||
| Completed |
NCT01408771 -
"Swallow my Urine Back" : Inhibition of Detrusor Overactivity by Swallowing Maneuver
|
N/A |